FACTORS INVOLVED IN IMMUNE MODULATION OF BOVINE LEUKEMIA VIRUS INFECTION NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


FACTORS INVOLVED IN IMMUNE MODULATION OF BOVINE LEUKEMIA VIRUS INFECTION

Diss Abstr Int [B]; 51(9):4223 1991. Unique Identifier : AIDSLINE ICDB/91676122
Pool WV; Louisiana State Univ. and Agricultural and Mechanical Coll.


Abstract: Bovine leukemia virus (BLV) is an exogenous type-C retrovirus which can induce an aleukemic (AL) stage, a persistent lymphocytotic (PL) stage, or a lymphosarcomatous stage in infected animals. After experimental infection with BLV, whole blood and serum samples were obtained from 12 holstein heifers for 103 wk and used to correlate clinical signs (visual observation and WBC counts) with changes in humoral immune response (Agar gel immunodiffusion using envelope gp50 as primary antigen, and ELISA and Western immunoblots using whole BLV as antigen). Monoclonal antibodies against BLV envelope gp50 and gag p24 were produced to confirm reactivity to specific proteins for the various assays. To confirm reactivity of monoclonals and produce large amounts of selected proteins for later studies of BLV, the genes for env, gag, and px were cloned into eukaryotic expression vectors. After transfection of appropriate plasmids, correct expression of cloned genes was confirmed using monoclonals and indirect immunofluorescence for gp50 and p24 and CAT assay for px. Total lymphocyte counts indicated 6 cattle reached the PL stage during the 103 wk postinfection (PI). Cows progressed through three transient disease stages in the first 3 mo PI: transient eosinophilia, lymph node enlargement and lymphocytosis. Of the 6 cattle demonstrating early transient lymph node enlargement, 5/6 were AL. Changes in the humoral immune response to BLV were best detected using Western immunoassays. AL cattle were more likely to have an increased antibody response to the gag protein p24 early PI as compared to PL cattle. PL animals usually reached their highest p24 antibody responses after conversion to the PL stage. Antibody response to env gp50 increased as a function of time PI regardless of disease stage. PL cattle tended to recognize a greater number of the lesser gag proteins, p15, p12 and p10 in the first year PI than AL cattle. All cattle decreased markedly in their reactivity to any of these lesser proteins after 51 wk PI. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD91-04163).
Keywords: Animal Antibodies, Monoclonal/DIAGNOSTIC USE Antibodies, Viral/ANALYSIS Female Gene Products, gag/IMMUNOLOGY Leukemia Virus, Bovine/*IMMUNOLOGY Leukemia, Experimental/*IMMUNOLOGY Viral Envelope Proteins/IMMUNOLOGY THESISKWDanimalantibodies,monoclonal/diagnosticuseantibodies,viral/analysisfemalegeneproducts,gag/immunologyleukemiavirus,bovine/KWDimmunologyleukemia,experimental/KWDimmunologyviralenvelopeproteins/immunologythesis
912130
M91C4081

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .